Tirzepatide in Type 2 Diabetes with Cardiovascular Disease: SURPASS-CVOT Evidence
Tirzepatide can be used as a glucose-lowering agent in adults with type 2 diabetes and established cardiovascular disease, but it should not replace SGLT-2 inhibitors or GLP-1 receptor agonists that have proven cardiovascular benefits—instead, combine tirzepatide with an SGLT-2 inhibitor if prioritizing weight loss over established cardiovascular protection. 1
The SURPASS-CVOT Trial Results
The SURPASS-CVOT trial (2025) demonstrated that tirzepatide was noninferior to dulaglutide for the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke (12.2% vs 13.1%; HR 0.92,95.3% CI 0.83-1.01), but did not achieve statistical superiority (P=0.09) 2. This is a critical distinction—tirzepatide proved safe but not definitively superior to an established GLP-1 RA for cardiovascular outcomes.
Key Trial Details:
- 13,165 patients with type 2 diabetes and atherosclerotic cardiovascular disease
- Mean age 64 years, mean diabetes duration 14.7 years, baseline HbA1c 8.4%
- 65% had coronary disease, 19% prior stroke, 25% peripheral artery disease 2
Clinical Decision Algorithm
For Patients Already on GLP-1 RA or SGLT-2 Inhibitor:
Do not switch to tirzepatide monotherapy. The evidence for cardiovascular and kidney protection with GLP-1 RAs and SGLT-2 inhibitors is higher certainty (strong recommendations) compared to tirzepatide's moderate-to-low certainty evidence 1, 3.
For Treatment-Naive Patients with Established ASCVD:
First-line: SGLT-2 inhibitor + GLP-1 RA combination (both with proven cardiovascular benefit) 3
- This provides additive cardiovascular and kidney protection with high certainty evidence
Alternative if weight loss is the primary concern:
For Patients Prioritizing Weight Loss:
If replacing a GLP-1 RA with tirzepatide, you must initiate or continue an SGLT-2 inhibitor to maintain cardiovascular and kidney protection 1. This is non-negotiable for patients with established ASCVD or multiple risk factors.
Evidence Quality and Certainty
The 2025 BMJ guideline explicitly states that tirzepatide has:
- Moderate certainty for weight loss benefits
- Low to very low certainty for cardiovascular and kidney outcomes 1
In contrast, GLP-1 RAs and SGLT-2 inhibitors have:
- High certainty evidence for cardiovascular death, myocardial infarction, stroke prevention
- Strong recommendations for use in patients with established ASCVD 3
Critical Caveats
Never combine tirzepatide with GLP-1 receptor agonists—they share overlapping mechanisms and this combination is not indicated 1.
The SURPASS-CVOT trial showed more gastrointestinal adverse events with tirzepatide compared to dulaglutide 2, which may limit tolerability in some patients.
Practical Positioning
Tirzepatide occupies a specific niche: it is the preferred agent when maximal weight loss is the therapeutic priority in a patient with type 2 diabetes and obesity, but only when combined with proven cardiovascular protective medications (SGLT-2 inhibitors) 1. It should not be positioned as a cardiovascular risk-reduction agent based on current evidence, as it failed to demonstrate superiority over dulaglutide and has lower certainty evidence compared to established GLP-1 RAs like semaglutide or dulaglutide 2.
The 2025 ADA Standards explicitly recommend GLP-1 RAs "with demonstrated cardiovascular benefit" for ASCVD risk reduction 3—tirzepatide's noninferiority result does not meet this threshold for a primary cardiovascular indication.